Literature DB >> 21896915

Helicobacter pylori resistance to rifabutin in the last 7 years.

Toshihiro Nishizawa1, Hidekazu Suzuki, Juntaro Matsuzaki, Hiroe Muraoka, Hitoshi Tsugawa, Kenro Hirata, Toshifumi Hibi.   

Abstract

A low rate of resistance (0.24%) to rifabutin was noted in Helicobacter pylori strains isolated from 414 Japanese patients. The only rifabutin-resistant strain detected showed a point mutation in the rpoB gene and was isolated from a patient with a history of rifampin treatment for pulmonary tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21896915      PMCID： PMC3195021          DOI： 10.1128/AAC.05437-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Rifampin and rifabutin resistance mechanism in Helicobacter pylori.

Authors:  M Heep; D Beck; E Bayerdörffer; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Hiroe Muraoka; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 3.  Helicobacter pylori eradication therapy.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Toshifumi Hibi
Journal:  Future Microbiol       Date:  2010-04       Impact factor: 3.165

4.  Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Hitoshi Tsugawa; Hiroe Muraoka; Juntaro Matsuzaki; Kenro Hirata; Fumiaki Ikeda; Masahiko Takahashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

5.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.

Authors:  Kenro Hirata; Hidekazu Suzuki; Toshihiro Nishizawa; Hitoshi Tsugawa; Hiroe Muraoka; Yoshimasa Saito; Juntaro Matsuzaki; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2010-05       Impact factor: 4.029

7.  Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.

Authors:  Shoji Suzuki; Hidekazu Suzuki; Toshihiro Nishizawa; Fumihiko Kaneko; Sumire Ootani; Hiroe Muraoka; Yoshimasa Saito; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Digestion       Date:  2009-01-14       Impact factor: 3.216

8.  Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.

Authors:  T Masaoka; H K SuzukiKurabayashi; A G Kamiya; H Ishii
Journal:  Aliment Pharmacol Ther       Date:  2004-07       Impact factor: 8.171

9.  Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Izumi Nakagawa; Eisuke Iwasaki; Tatsuhiro Masaoka; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 4.029

10.  The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice.

Authors:  D Van der Poorten; P H Katelaris
Journal:  Aliment Pharmacol Ther       Date:  2007-09-28       Impact factor: 8.171
View more
  15 in total

1.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

2.  Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Takama Maekawa; Naohiko Harada; Tatsuya Toyokawa; Toshio Kuwai; Masanori Ohara; Takahiro Suzuki; Masahiro Kawanishi; Kenji Noguchi; Toshiyuki Yoshio; Shinji Katsushima; Hideo Tsuruta; Eiji Masuda; Munehiro Tanaka; Shunsuke Katayama; Norio Kawamura; Yuko Nishizawa; Toshifumi Hibi; Masahiko Takahashi
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 3.  Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Clin Microbiol Rev       Date:  2022-04-11       Impact factor: 50.129

4.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-01-19       Impact factor: 4.623

Review 5.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

Review 6.  Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki
Journal:  Front Mol Biosci       Date:  2014-10-24

7.  Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective.

Authors:  Vasilios Papastergiou; Nicoletta Mathou; Sophia Licousi; Aikaterini Evgenidi; Konstantina D Paraskeva; Athanasios Giannakopoulos; Pinelopi-Zoi Stavrou; Evangelia Platsouka; John A Karagiannis
Journal:  Ann Gastroenterol       Date:  2017-11-30

Review 8.  World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

Authors:  Hidekazu Suzuki; Hideki Mori
Journal:  J Gastroenterol       Date:  2017-11-14       Impact factor: 7.527

Review 9.  Current Status of the Third-Line Helicobacter pylori Eradication.

Authors:  Jae Ho Choi; Young Joo Yang; Chang Seok Bang; Jae Jun Lee; Gwang Ho Baik
Journal:  Gastroenterol Res Pract       Date:  2018-05-02       Impact factor: 2.260

10.  Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics.

Authors:  Muhammad Miftahussurur; Hafeza Aftab; Pradeep Krishna Shrestha; Rabi Prakash Sharma; Phawinee Subsomwong; Langgeng Agung Waskito; Dalla Doohan; Kartika Afrida Fauzia; Yoshio Yamaoka
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-15       Impact factor: 4.887
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.